We report a retrospective analysis of VZV infection after haematopoietic stem cell transplantation (HSCT) in children. Thirty-three (30%) of the total 109 children who were transplanted during a 7 year period developed post-transplant VZV infection. Twenty-four of these 33 (73%) children had VZV infection within 1 year following HSCT. The cumulative incidences of post-transplant VZV infection at 1 and 5 years were 26% and 45%, respectively. The positive and negative predictive values of pretransplant VZV serology in recipients on the development of HZ following HSCT were 39% and 88%, respectively. Pretransplant VZV seropositivity in recipients was the only risk factor for post-transplant herpes zoster (HZ) infection on multivariate analysis. All patients responded to acyclovir. The median duration of VZV infection was 5 days. Three (11%) and one (3%) children with HZ developed visceral dissemination and post-herpetic neuralgia, respectively. No mortality was directly attributed to VZV infection. VZV infection remains a major cause of morbidity in children after HSCT. Further studies are warranted to evaluate the potential use of VZV vaccine in these children. Bone Marrow Transplantation (2000) 25, 167-172. Keywords: haematopoietic stem cell transplantation; herpes zoster; paediatric; varicella-zoster virus Varicella-zoster virus (VZV) is a herpes virus that causes chickenpox (CP) as a primary infection and herpes zoster (HZ) when the latent virus is reactivated. It is a significant cause of morbidity and mortality in immunocompromised patients. Ten percent of children with leukaemia on maintenance chemotherapy died of VZV infection in the preacyclovir era.
Varicella-zoster virus (VZV) is a herpes virus that causes chickenpox (CP) as a primary infection and herpes zoster (HZ) when the latent virus is reactivated. It is a significant cause of morbidity and mortality in immunocompromised patients. Ten percent of children with leukaemia on maintenance chemotherapy died of VZV infection in the preacyclovir era. 1 Haematopoietic stem cell transplantation (HSCT) is now the treatment of choice for some malignant and nonmalignant conditions in children. However, these patients are at high risk of having severe VZV infection because of significant and prolonged immunosuppression in the post-transplant period. The incidence of VZV infec-tion in children following HSCT varied from 23% to 67%. [2] [3] [4] [5] [6] Herpes zoster is one of the common late infections in post-transplant patients. The median onset of HZ following HSCT occurred at the fifth month. 7 However, risk factors for post-transplant VZV infection in children are less well defined because there are few reports on this subject. In this study, we review the incidence, risk factors, treatment and clinical outcome of VZV infection in children who underwent HSCT at our centre.
Patients and methods

Study population and design
A total of 109 consecutive children who underwent HSCT in the Department of Paediatrics of the Prince of Wales Hospital, Hong Kong between February 1991 and June 1998 were included in this study. Management protocols on pretransplant conditioning regimens and GVHD prophylaxis following HSCT in our patients have been published previously. [8] [9] [10] Patients with a history of herpes simplex infection or who were seropositive for this virus received acyclovir at 250 mg/m 2 twice daily i.v. from day 0 for 30 days. Children seropositive for CMV who received allogeneic HSCT or who received their transplant from a seropositive donor were given acyclovir at 500 mg/m 2 every 8 h i.v. from day −7 until day 30 before 1992. Prophylaxis against CMV infection was then changed to ganciclovir at 5 mg/kg/day 3 days per week i.v. from engraftment until day 84. Also, all post-transplant patients before 1995 and those who received HSCT from unrelated donor or HLAmismatched transplants after 1995 received prophylactic Ig (IVIG) at 500 mg/kg every 2 weeks i.v. from day 1 for 3 months. We conducted a retrospective review of the case records for occurrence of VZV in our post-transplant patients. One case record was unavailable for analysis of occurrence of VZV infection.
Definition of VZV infection
Varicella-zoster virus infection was defined by the appearance of typical cutaneous vesicular lesions or demonstration of VZV by Ag detection or virus isolation. VZV infection was classified as CP when there was generalized onset of vesicular skin eruptions and no dermatomal localization was found during the course of the disease. HZ was diagnosed by the presence of vesicular lesions in a derma-tomal distribution. Cutaneous dissemination of HZ was defined as the subsequent appearance of lesions in noncontiguous dermatomes. Visceral dissemination of either CP or HZ was defined as histological or culture evidence of internal organ involvement or as clinical evidence of internal organ involvement in the absence of other identified pathogens that might have accounted for the clinical syndrome. VZV Ab was measured by either complement fixation or enzyme immunoassay. Seropositivity to VZV was defined as either a viral titre of у10 by the complement fixation test or by a positive result with the latter method.
Data analysis
The potential risk factors for post-transplant HZ which were included in statistical analysis were the age of children at diagnosis of underlying diseases or at HSCT, gender of patients, nature of underlying diseases, pretransplant VZV seropositivity in donors or recipients, details of HSCT such as allogeneic BMT, numbers of nucleated stem cells infused into recipients, use of TBI or BU in conditioning regimens, use of prophylactic CSF, presence of acute or chronic GVHD, timing of immune reconstitution as shown by T helper to suppressor cell ratio and post-transplant infection prophylaxis with acyclovir, ganciclovir or IVIG. The effects of these risk factors on HZ infection were compared with the Kaplan-Meier method by the log rank test. Comparisons between different groups of patients or clinical information were made with the 2 test for categorical data or unpaired Student's t-test for numerical variables. The simultaneous effect of several risk factors on the occurrence of post-transplant HZ was studied by proportional hazards regression with the Cox model. P values less than 0.05 were considered to be significant.
Results
The median ages of patients at diagnosis of underlying diseases and at HSCT were 2.8 and 9.2 years (ranges 0-14.5 years and 1.3-21.1 years), respectively. Thirteen patients had autologous transplants and 96 received allogeneic HSCT during the 7-year period. All patients who received autologous transplants suffered from underlying malignancies whereas only 44 (46%) of allogeneic HSCT were performed for malignant diseases. The median ages of patients at transplant did not differ between these two groups of HSCT (allogeneic 10 years and autologous 7.9 years). Engraftment occurred significantly earlier in patients after allogeneic (median 18 days, range 10-53 days) than autologous HSCT (median 34 days, range 10-102 days) (P = 0.042). T helper to suppressor cell (CD4/CD8) ratios at 3 months post transplant were available in seven (54%) patients after autologous transplantation and 49 (51%) children after allogeneic BMT. CD4/CD8 ratios at 3 months post transplant were significantly lower in those after autologous (median 0.31, range 0.1-1) than allogeneic (median 0.61, range 0.22-2.17) HSCT (P = 0.049).
Thirty-three (31%) children developed post-transplant VZV infection. Seventeen (52%) of these 33 patients suffered from VZV infection during the first 6 months after transplant and 24 children (73%) had VZV infection by 1 year. A Kaplan-Meier estimate showed that the probabilities of developing VZV (CP and HZ) infection in the whole group at 6 months and 1 year were 17% and 26%, respectively. Forty-five percent of children were estimated as likely to develop VZV infection at 5 years post HSCT. The probabilities for post-transplant HZ alone at 1 and 5 years were 24% and 34%, respectively. Details of CP and HZ in our patients are described in Table 1 . Six patients developed CP, 14 patients developed localized HZ and 13 children suffered from disseminated HZ after HSCT. The median onset of all post-transplant VZV infections was 181 days (range 1-1058 days). There was no significant difference between median time of onset of infection for those with CP and HZ (544 days and 124 days, respectively, P = 0.066). All children who received autologous HSCT developed HZ, whereas six (22%) of 27 patients with posttransplant VZV infection were due to primary VZV infection.
Three children were diagnosed as having HZ with visceral dissemination. One of them had shingles that was noticed on day 196 after transplant. His serum alanine transaminase started to increase 3 days afterwards with the highest level being 1411 IU/l at 24 days following the onset of skin lesions. Skin vesicles lasted for 5 days whereas liver derangement persisted for 60 days despite the use of intravenous acyclovir (500 mg/m 2 every 8 h i.v.). He suffered from acute grade I GVHD on day 90 which was easily controlled by immunosuppressive agents. The second child had cutaneous dissemination of HZ affecting four dermatomes at 36 days following HSCT. His serum alanine transaminase was elevated to 170 IU/l on the day of appearance of skin rash. There was no evidence of GVHD. Another patient developed aseptic meningitis with fever, headache and repeated vomiting at 5 days following the onset of shingles which involved multiple dermatomes. Cerebrospinal fluid (CSF) had 14 white blood cells per l (95% lymphocytes). Microbiological investigations of CSF were Table 1 Details of post-transplant VZV infection
Features of VZV infection Results
Chickenpox (n = 6) all negative. These children all recovered from VZV infection without long term complications, after intravenous acyclovir treatment. With regard to the clinical outcome, 12 (36%) of 33 patients with post-transplant VZV infection were treated with intravenous acyclovir, 10 (30%) with oral acyclovir and the others received intravenous followed by oral acyclovir. Median duration of VZV infection in our children was 5 days (range 3-60 days). Only one patient who underwent allogeneic HSCT developed neuralgia that lasted for 10 days following HZ. None of our patients had more than one episode of CP or HZ. No mortality was directly related to VZV infection. Pre-transplant VZV serology was available in 108 HSCT recipients. Forty-nine (45%) patients were VZV seropositive. A past history of CP was present in 42 (39%) patients and 29 (69%) of them were found to have VZV Ab before HSCT. Forty-one (66%) of 62 children who did not suffer from CP before HSCT were seronegative. Nineteen (39%) of 49 VZV seropositive children suffered from post-transplant HZ, whereas seven (12%) of 59 VZV seronegative patients had this infection. Four of the latter seven children had a past history of CP. The positive (PPV) and negative predictive values (NPV) of pretransplant VZV serology in recipients for post-transplant HZ were 39% and 88%, respectively. The corresponding figures when the pretransplant VZV serology was considered only in those recipients with a past history of CP were 34% and 69%. When the analysis of post-transplant HZ was limited to the first year following HSCT, the PPV and NPV of pretransplant VZV serology were 31% and 90%, respectively. These values were even lower when a pretransplant history of CP and VZV serology were summated. Ten patients (32%) from a group of 31 pairs of seropositive transplant recipients and donors developed post-transplant HZ whereas six children (19%) developed HZ if either recipients or donors were VZV seropositive. There were only three patients (11%) who suffered from HZ in the group where both donors and recipients were seronegative.
All six patients who developed post-transplant CP and their respective donors were seronegative before HSCT. One of these patients had a history of CP before HSCT. Only one child who developed CP had a history of prior household contact with subjects with CP. Another thalassaemic boy received a bone marrow infusion from his younger brother who developed CP 1 week after the procedure. However, vesicular skin lesions were only noticed in this patient 157 days following transplant. None of our HSCT recipients with CP received VZV-specific immunoglobulin before the onset of post-transplant CP.
Clinical information of HSCT according to presence or absence of post-transplant VZV infection is summarized in Table 2 . Those who developed VZV infection within 1 year following HSCT are further detailed in Table 3 . Age at diagnosis of underlying disease for those children with HZ was older than for those without the infection. Pretransplant VZV seropositivity in recipients, patients older than or equal to 10 years of age at diagnosis of their underlying disease, conditioning regimen without BU and underlying malignancy were associated with increased incidences of post-transplant HZ, as shown in Table 2 . Proportional hazard regression revealed that only the first of these risk facBone Marrow Transplantation tors was associated with an increased risk of post-transplant HZ infection (P = 0.005). When analysis was limited to development of HZ within 1 year after HSCT, underlying malignancy, VZV seropositivity in transplant recipients, older age (у10 years) at diagnosis of underlying diseases, conditioning regimens without BU, TBI and autologous HSCT were significant risk factors for post-transplant VZV infection (Table 3) . Multivariate analysis similarly showed that pretransplant VZV seropositivity in recipients was the only significant risk factor for the development of HZ infection within 1 year after HSCT (P = 0.04).
Discussion
Haematopoietic stem cell transplantation is now the treatment of choice for some malignant and nonmalignant conditions in children. However, these patients are at high risk of having severe VZV infection because of severe and prolonged immunosuppression in the post-transplant period. The incidence of VZV infection in post-BMT children has varied from 23% to 67%. 4, 6, 7, 11, 12 Forty-five percent of our patients developed VZV infection by 5 years post HSCT which is consistent with data from the literature.
Herpes zoster caused by VZV reactivation affects 16.5% of children with ALL. 13 Subclinical VZV viraemia or HZ affected 41% VZV seropositive BMT recipients in one study. 14 Another study reported that subclinical VZV reactivation was detected in 26% of post-BMT patients. 15 HZ is one of the common late infections in post-BMT patients. This infection occurred as a result of VZV reactivation and only in those patients who had prior exposure to this virus. However, our result suggested that a clinical history of previous CP is not sufficiently accurate in predicting the presence of VZV-specific immunity. Only 29 (69%) of 42 transplant recipients with a previous history of CP were VZV seropositive. On the other hand, 41 (66%) children without a history of CP were VZV Ab negative. Hence, we observed a significant discrepancy between history of prior CP and VZV serology. The absence of either one of these factors does not exclude the possibility of post-transplant HZ.
Two previous reports showed that children developed post-transplant HZ earlier than adults.
2,5 However, our children developed HZ later, at a median time of 124 days after transplant in contrast to days 96 and 101 as reported by two Japanese groups. 2, 3 Median T helper to suppressor cell ratio in our subjects were 0.61 and 0.86 at 3 months and 1 year post transplant. This rapid immune reconstitution in our patients may explain the later onset of HZ. 6 Also, only a small proportion (22 of 96, 23%) of our children suffered from acute severe (grades 3 and 4) or chronic GVHD and required long-term immunosuppressive treatment. In a population-based study, none of the 118 apparently normal children with HZ developed long term complications. 16 It is also unusual to find severe complication from VZV infection in children after BMT. 2, 6 Our present study also confirmed the low complication rate (3%) from post-transplant VZV infection even in immunocompromised children following HSCT. 5 Several retrospective reviews have indicated that older age at BMT, underlying haematologic malignancies, VZV seropositive subjects, allogeneic transplantation, conditioning regimens containing TBI or BU, acute or chronic GVHD, post-transplant use of ATG and delayed immune reconstitution were risk factors for VZV infection following BMT. 2, 3, 7, 11, 12, [17] [18] [19] Patients who are non-immune to VZV are likely to develop CP after contact with this virus irrespective of whether they had HSCT or not. On the other hand, those who underwent HSCT are prone to develop VZV reactivation as a result of this profoundly immunosuppressive procedure. Hence, it is more clinically relevant to analyze the effects of various risk factors on post-transplant HZ rather than all VZV infections (CP and HZ). Our study indeed identified that several risk factors were associated with HZ following HSCT. However, multivariate analysis with the Cox model demonstrated that only pretransplant VZV seropositivity in recipients was associated with an increased incidence of HZ after HSCT. VZV Ab testing in transplant recipients also had a high negative predictive value of 88% for post-transplant HZ. Age and sex of recipients, presence of acute or chronic GVHD, details of transplant conditioning regimens and prophylactic use of antiviral agents or IVIG did not influence the occurrence of post-transplant HZ infection.
Previous studies reported similar incidences of posttransplant VZV infection in those who had undergone either autologous or allogeneic HSCT. 7, 11 Traditionally, autologous HSCT is believed to be a less immunosuppressive procedure as compared with allogeneic transplantation, with faster restoration of cellular immunity. 12 However, our autologous HSCT patients had later engraftment and delayed immune reconstitution as compared with those after allogeneic transplant. These children may thus be at increased risk of developing HZ. 3 Univariate analysis also revealed a higher incidence of early post-transplant HZ in those who received autologous HSCT. These findings may be explained by the fact that our autologous transplant children might be more immunocompromised in the early posttransplant period because all of them had underlying malignancies and received intensive pretransplant chemotherapy and radiation treatments. Recovery of lymphocyte transformation response to VZV antigen was found to be slower in post-transplant patients with leukaemia than in those with aplastic anaemia. 20 However, only 48% of our patients who underwent allogeneic HSCT suffered from underlying malignancies that required immunosuppressive treatment before transplant. Thus, the immunosuppressive effect of pretransplant anti-cancer treatments in this group of children would be lessened by the inclusion of the other half of the patients with benign conditions who had normal immune function before HSCT. Statistical analysis repeated only for patients with underlying malignancies who received autologous and allogeneic HSCT did not show any significant differences in time to engraftment (P = 0.062) and CD4/CD8 ratio at day 90 following HSCT (P = 0.14). Acyclovir is effective for treating VZV infections in immunocompromised patients. 21 Post-transplant VZV infection in leukaemic patients also reduced from 36% to 25% with the use of prophylactic acyclovir. 22 All patients in our study responded to either oral or intravenous acyclovir. However, the use of prophylactic acyclovir or ganciclovir did not affect the incidence of post-transplant VZV infection 11 as well as in our patients. Five of 21 post-transplant adults with acute leukaemia developed HZ within 1 month of acyclovir withdrawal. 21 Also, there is an increasing concern about emergence of acyclovir-resistant strains of VZV or herpes simplex virus. 23 A varicella vaccine collaborative study showed that varicella vaccination resulted in 86% protection of VZV infection after household contacts and a two-third reduction in HZ in children with leukaemia. 24 The use of varicella vaccine in these children may also be cost-effective. 25 Nevertheless, the optimal schedule of varicella vaccination in children after HSCT remains unclear. This vaccine is commercially available as a live-attenuated viral preparation that cannot be given to patients too early after transplant at a time before immune reconstitution occurs. On the other hand, most of the post-transplant VZV infection (73% in our study) occurs within the first year when patients are severely immunocompromised. The timely administration of this vaccine may protect post-transplant patients from early and severe VZV infection. For instance, our VZV seropositive children were found to be at high risk of havBone Marrow Transplantation ing HZ after HSCT. Early post-transplant VZV vaccination of these patients may boost their VZV-specific cellular immunity and thus protect them from having severe HZ. 26 Recent studies have also suggested that active immunization of post-BMT patients with live-attenuated varicella vaccine is effective in reducing VZV infection. 4 Another clinical trial documented that children with leukaemia who received VZV vaccine had a lower incidence of HZ (3.6% vs 13.1%) as compared with those after natural infection. 27 Thus, it is worthwhile studying the efficacy of pretransplant vaccination of VZV for seronegative children.
In conclusion, VZV infection is common in children after HSCT. The absence of a previous history of CP and VZVspecific Ab are not reliable indicators against a patient developing post-transplant HZ. We show that VZV sero-positive recipients are at high risk for developing post-transplant HZ.
